Everolimus

What is Everolimus?

Everolimus is an immunosuppressive medication that belongs to a class of drugs called mTOR (mechanistic target of rapamycin) inhibitors. It is primarily used to prevent organ transplant rejection and to treat certain types of cancer. The drug works by suppressing the immune system and inhibiting cell growth pathways that promote tumor development.

Uses

Everolimus has several approved medical applications:

• Kidney transplant rejection prevention: Used in combination with other immunosuppressive drugs to prevent the body from rejecting a transplanted kidney
• Liver transplant rejection prevention: Helps maintain transplanted liver function by preventing immune system attacks on the new organ
• Renal cell carcinoma: Treats advanced kidney cancer that has not responded to other targeted therapies
• Neuroendocrine tumors: Used for progressive pancreatic neuroendocrine tumors and lung or gastrointestinal neuroendocrine tumors
• Tuberous sclerosis complex: Treats benign kidney tumors (angiomyolipomas) and brain tumors (subependymal giant cell astrocytomas) associated with this genetic condition

How it works

Everolimus blocks the mTOR protein, which plays a crucial role in cell growth, proliferation, and survival. By inhibiting this pathway, the drug prevents immune cells from multiplying and attacking transplanted organs, while also stopping cancer cells from growing and dividing. This dual mechanism makes it effective both as an immunosuppressant and as an anti-cancer agent.

Side effects

Common side effects include:

Submit Your Paper

• Mouth ulcers and stomatitis
• Fatigue and weakness
• Diarrhea and nausea
• Decreased appetite
• Skin rash
• Swelling of hands, feet, or ankles
• Headache
• Cough and shortness of breath

Serious side effects requiring immediate medical attention:

• Severe lung inflammation (pneumonitis)
• Serious infections due to immune suppression
• Kidney problems or decreased kidney function
• Severe mouth ulcers that interfere with eating or drinking
• Signs of liver problems such as yellowing of skin or eyes

Warnings and precautions

• Increased infection risk: Everolimus suppresses the immune system, making patients more susceptible to bacterial, viral, and fungal infections
• Pregnancy and breastfeeding: This medication can harm an unborn baby and should not be used during pregnancy; effective contraception is required during treatment and for 8 weeks after stopping
• Kidney and liver function: Regular monitoring is essential as everolimus can worsen existing kidney or liver problems
• Wound healing: The drug may impair wound healing, so timing around surgeries requires careful consideration
• Live vaccines: Patients should avoid live vaccines while taking everolimus due to the risk of developing the infection the vaccine is meant to prevent

Interactions

Everolimus has numerous important drug interactions:

• Ketoconazole and other strong CYP3A4 inhibitors: Significantly increase everolimus levels, requiring dose reduction
• Rifampin and other CYP3A4 inducers: Decrease everolimus effectiveness by reducing blood levels
• ACE inhibitors: May increase the risk of angioedema (severe swelling of face, lips, or throat)
• Live vaccines: Should be avoided due to risk of developing vaccine-preventable infections
• Grapefruit juice: Can increase everolimus levels and should be avoided
• St. John’s Wort: May reduce everolimus effectiveness by increasing its breakdown in the body
• Cyclosporine: When used together in transplant patients, requires careful dose adjustment and monitoring
• Warfarin: May affect blood clotting times, requiring more frequent monitoring

Check interactions with the GMJ Interaction Checker

Dosage

Everolimus dosing varies significantly based on the condition being treated and individual patient factors. For kidney transplant patients, typical starting doses range from 0.75 mg to 1.5 mg twice daily, adjusted based on blood levels. Cancer patients may receive 5-10 mg once daily, depending on the specific type of cancer and tolerance. For tuberous sclerosis complex, dosing starts at 4.5 mg per square meter of body surface area daily, divided into two doses. All dosing must be individualized and determined by a healthcare provider based on blood level monitoring, kidney function, and patient response. Regular blood tests are essential to ensure optimal dosing and monitor for side effects.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).